<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD10420000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>P02766</UniProt_ID>
  <Seq_Length>147</Seq_Length>
  <Molecule_Weight>15887</Molecule_Weight>
  <KEGG_ID>hsa:7276</KEGG_ID>
  <Function_Summary>Thyroid hormone-binding protein. Probably transports thyroxine from the bloodstream to the brain.</Function_Summary>
  <Pfam_ID>PF00576:Transthyretin</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>94</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>98</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>ATTR</Alias>
      <Alias>TBPA</Alias>
      <Alias>Prealbumin</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Protein precursor of thyroid hormones which are secreted by the thymus gland and participate in the development of the lymphoid system as well as the maturation of the cellular immune response. Also used for proteins which bind thyroid hormones or thyroid hormone receptor antagonists.</Detail>
      <Keyword>Thyroid hormone</Keyword>
      <Ontology_ID>KW-0795</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>The action characteristic of a hormone, any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action. The term was originally applied to agents with a stimulatory physiological action in vertebrate animals (as opposed to a chalone, which has a depressant action). Usage is now extended to regulatory compounds in lower animals and plants, and to synthetic substances having comparable effects; all bind receptors and trigger some biological process.</Detail>
      <Keyword>Hormone activity</Keyword>
      <Ontology_ID>GO:0005179</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any hormone, naturally occurring substances secreted by specialized cells that affect the metabolism or behavior of other cells possessing functional receptors for the hormone.</Detail>
      <Keyword>Hormone binding</Keyword>
      <Ontology_ID>GO:0042562</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>55</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>126</Position>
      <Original>Thr</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>78</Position>
      <Original>Leu</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>80</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>75</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>122</Position>
      <Original>Pro</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>26</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>134</Position>
      <Original>Tyr</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>117</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>131</Position>
      <Original>Leu</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>93</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>104</Position>
      <Original>Ile</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>111</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>104</Position>
      <Original>Ile</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>65</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>144</Position>
      <Original>Asn</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>117</Position>
      <Original>Ala</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>84</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>136</Position>
      <Original>Tyr</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>136</Position>
      <Original>Tyr</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>127</Position>
      <Original>Ile</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>38</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>142</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>81</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>65</Position>
      <Original>Ala</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>110</Position>
      <Original>His</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>33</Position>
      <Original>Met</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>69</Position>
      <Original>Thr</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>74</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>67</Position>
      <Original>Gly</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>129</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>56</Position>
      <Original>Ala</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>97</Position>
      <Original>Ser</Original>
      <Variation>Tyr</Variation>
    </Muntion>
    <Muntion>
      <Position>70</Position>
      <Original>Ser</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>139</Position>
      <Original>Thr</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>62</Position>
      <Original>Glu</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>94</Position>
      <Original>Asp</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>121</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>140</Position>
      <Original>Ala</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>67</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>67</Position>
      <Original>Gly</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>109</Position>
      <Original>Glu</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>48</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>70</Position>
      <Original>Ser</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>98</Position>
      <Original>Tyr</Original>
      <Variation>Phe</Variation>
    </Muntion>
    <Muntion>
      <Position>134</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Phe</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>65</Position>
      <Original>Ala</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>142</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Phe</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>43</Position>
      <Original>Ser</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>44</Position>
      <Original>Pro</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>58</Position>
      <Original>Asp</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>40</Position>
      <Original>Val</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Val</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>127</Position>
      <Original>Ile</Original>
      <Variation>Met</Variation>
    </Muntion>
    <Muntion>
      <Position>114</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>30</Position>
      <Original>Cys</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>81</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>62</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>74</Position>
      <Original>Glu</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>124</Position>
      <Original>Arg</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>69</Position>
      <Original>Thr</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>90</Position>
      <Original>Lys</Original>
      <Variation>Asn</Variation>
    </Muntion>
    <Muntion>
      <Position>104</Position>
      <Original>Ile</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>124</Position>
      <Original>Arg</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>75</Position>
      <Original>Leu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>67</Position>
      <Original>Gly</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>89</Position>
      <Original>Tyr</Original>
      <Variation>His</Variation>
    </Muntion>
    <Muntion>
      <Position>72</Position>
      <Original>Ser</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>79</Position>
      <Original>Thr</Original>
      <Variation>Lys</Variation>
    </Muntion>
    <Muntion>
      <Position>91</Position>
      <Original>Val</Original>
      <Variation>Ala</Variation>
    </Muntion>
    <Muntion>
      <Position>58</Position>
      <Original>Asp</Original>
      <Variation>Val</Variation>
    </Muntion>
    <Muntion>
      <Position>78</Position>
      <Original>Leu</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>38</Position>
      <Original>Asp</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Phe</Original>
      <Variation>Ile</Variation>
    </Muntion>
    <Muntion>
      <Position>54</Position>
      <Original>Arg</Original>
      <Variation>Thr</Variation>
    </Muntion>
    <Muntion>
      <Position>32</Position>
      <Original>Leu</Original>
      <Variation>Pro</Variation>
    </Muntion>
    <Muntion>
      <Position>61</Position>
      <Original>Trp</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>53</Position>
      <Original>Phe</Original>
      <Variation>Cys</Variation>
    </Muntion>
    <Muntion>
      <Position>64</Position>
      <Original>Phe</Original>
      <Variation>Ser</Variation>
    </Muntion>
    <Muntion>
      <Position>88</Position>
      <Original>Ile</Original>
      <Variation>Leu</Variation>
    </Muntion>
    <Muntion>
      <Position>109</Position>
      <Original>Glu</Original>
      <Variation>Gln</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Val</Original>
      <Variation>Gly</Variation>
    </Muntion>
    <Muntion>
      <Position>73</Position>
      <Original>Gly</Original>
      <Variation>Glu</Variation>
    </Muntion>
    <Muntion>
      <Position>50</Position>
      <Original>Val</Original>
      <Variation>Leu</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The chemical reactions and pathways involving retinol, one of the three compounds that makes up vitamin A.</Detail>
      <Keyword>Retinol metabolic process</Keyword>
      <Ontology_ID>GO:0042572</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore.</Detail>
      <Keyword>Transport</Keyword>
      <Ontology_ID>GO:0006810</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>62</Position>
      <PTM_Type>4-carboxyglutamate</PTM_Type>
    </PTM>
  </PTM_List>
  <Molecule_Seq>
    <Protein_Seq>MASHRLLLLCLAGLVFVSEAGPTGTGESKCPLMVKVLDAVRGSPAINVAVHVFRKAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDTKSYWKALGISPFHEHAEVVFTANDSGPRRYTIAALLSPYSYSTTAVVTNPKE</Protein_Seq>
    <DNA_Seq>GTTGACTAAGTCAATAATCAGAATCAGCAGGTTTGCAGTCAGATTGGCAGGGATAAGCAGCCTAGCTCAGGAGAAGTGAGTATAAAAGCCCCAGGCTGGGAGCAGCCATCACAGAAGTCCACTCATTCTTGGCAGGATGGCTTCTCATCGTCTGCTCCTCCTCTGCCTTGCTGGACTGGTATTTGTGTCTGAGGCTGGCCCTACGGGCACCGGTGAATCCAAGTGTCCTCTGATGGTCAAAGTTCTAGATGCTGTCCGAGGCAGTCCTGCCATCAATGTGGCCGTGCATGTGTTCAGAAAGGCTGCTGATGACACCTGGGAGCCATTTGCCTCTGGGAAAACCAGTGAGTCTGGAGAGCTGCATGGGCTCACAACTGAGGAGGAATTTGTAGAAGGGATATACAAAGTGGAAATAGACACCAAATCTTACTGGAAGGCACTTGGCATCTCCCCATTCCATGAGCATGCAGAGGTGGTATTCACAGCCAACGACTCCGGCCCCCGCCGCTACACCATTGCCGCCCTGCTGAGCCCCTACTCCTATTCCACCACGGCTGTCGTCACCAATCCCAAGGAATGAGGGACTTCTCCTCCAGTGGACCTGAAGGACGAGGGATGGGATTTCATGTAACCAAGAGTATTCCATTTTTACTAAAGCAGTGTTTTCACCTCATATGCTATGTTAGAAGTCCAGGCAGAGACAATAAAACATTCCTGTGAAAGGCACTTTTCATTCCACTTTAACTTGATTTTTTAAATTCCCTTATTGTCCCTTCCAAAAAAAAGAGAATCAAAATTTTACAAAGAATCAAAGGAATTCTAGAAAGTATCTGGGCAGAACGCTAGGAGAGATCCAAATTTCCATTGTCTTGCAAGCAAAGCACGTATTAAATATGATCTGCAGCCATTAAAAAGACACATTCTGTAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Serum</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Protein complex</CellLocal>
      <Ontology_ID>GO:0043234</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Amyloid</CellLocal>
      <Ontology_ID>KW-0034</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular space</CellLocal>
      <Ontology_ID>GO:0005615</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>TTR</Gene_Name>
    <Gene_Alias>PALB</Gene_Alias>
    <Gene_ID>7276</Gene_ID>
    <Genbank_ACCN>NM_000371</Genbank_ACCN>
    <Protein_ACCN>NP_000362</Protein_ACCN>
    <HGNC_ID>12405</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/7276</Gene_URL>
    <UCSC_ID>uc002kwx.4</UCSC_ID>
    <EMBL_ID>ENSG00000118271</EMBL_ID>
  </Gene>
  <Disease_List>
    <Disease>
      <Disease_Name>Liver Cirrhosis</Disease_Name>
      <Disease_Detail>Liver Cirrhosis</Disease_Detail>
      <Disease_DB>LVR012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/liver_cirrhosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Choroid Plexus Papilloma</Disease_Name>
      <Disease_Detail>Choroid Plexus Papilloma</Disease_Detail>
      <Disease_DB>CHR029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/choroid_plexus_papilloma?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Amyloidosis, Finnish Type</Disease_Name>
      <Disease_Detail>Familial Amyloidosis, Finnish Type</Disease_Detail>
      <Disease_DB>FML249</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_amyloidosis_finnish_type?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Cerebral Amyloid Angiopathy</Disease_Name>
      <Disease_Detail>Cerebral Amyloid Angiopathy</Disease_Detail>
      <Disease_DB>CRB019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/cerebral_amyloid_angiopathy?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Al Amyloidosis</Disease_Name>
      <Disease_Detail>Al Amyloidosis</Disease_Detail>
      <Disease_DB>ALM001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/al_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperthyroxinemia Dystransthyretinemic Euthyroidal</Disease_Name>
      <Disease_Detail>Hyperthyroxinemia Dystransthyretinemic Euthyroidal</Disease_Detail>
      <Disease_DB>HYP571</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperthyroxinemia_dystransthyretinemic_euthyroidal?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carpal Tunnel Syndrome, Familial</Disease_Name>
      <Disease_Detail>Carpal Tunnel Syndrome</Disease_Detail>
      <Disease_DB>CRP017</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carpal_tunnel_syndrome_familial?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Glossitis</Disease_Name>
      <Disease_Detail>Glossitis</Disease_Detail>
      <Disease_DB>GLS007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/glossitis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Molybdenum Cofactor Deficiency</Disease_Name>
      <Disease_Detail>Molybdenum Cofactor Deficiency</Disease_Detail>
      <Disease_DB>MLY001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/molybdenum_cofactor_deficiency?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Siderosis</Disease_Name>
      <Disease_Detail>Siderosis</Disease_Detail>
      <Disease_DB>SDR002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/siderosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Paresthesia</Disease_Name>
      <Disease_Detail>Paresthesia</Disease_Detail>
      <Disease_DB>PRS063</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/paresthesia?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amyloidosis</Disease_Name>
      <Disease_Detail>Amyloidosis</Disease_Detail>
      <Disease_DB>AMY004</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amyloidosis, Secondary</Disease_Name>
      <Disease_Detail>Amyloidosis</Disease_Detail>
      <Disease_DB>AMY053</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amyloidosis_secondary?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Oculoleptomeningeal Amyloidosis</Disease_Name>
      <Disease_Detail>Familial Oculoleptomeningeal Amyloidosis</Disease_Detail>
      <Disease_DB>FML141</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_oculoleptomeningeal_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Finnish Type Amyloidosis</Disease_Name>
      <Disease_Detail>Finnish Type Amyloidosis</Disease_Detail>
      <Disease_DB>FNN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/finnish_type_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Protein-Energy Malnutrition</Disease_Name>
      <Disease_Detail>Protein-Energy Malnutrition</Disease_Detail>
      <Disease_DB>PRT038</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/protein_energy_malnutrition?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Restrictive Cardiomyopathy</Disease_Name>
      <Disease_Detail>Restrictive Cardiomyopathy</Disease_Detail>
      <Disease_DB>RST002</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/restrictive_cardiomyopathy?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Obstructive Jaundice</Disease_Name>
      <Disease_Detail>Obstructive Jaundice</Disease_Detail>
      <Disease_DB>OBS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obstructive_jaundice?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Takayasu's Arteritis</Disease_Name>
      <Disease_Detail>Takayasu's Arteritis</Disease_Detail>
      <Disease_DB>TKY001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/takayasus_arteritis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Dysalbuminemic Hyperthyroxinemia</Disease_Name>
      <Disease_Detail>Dysalbuminemic Hyperthyroxinemia</Disease_Detail>
      <Disease_DB>DYS070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/dysalbuminemic_hyperthyroxinemia?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Familial Amyloid Cardiomyopathy</Disease_Name>
      <Disease_Detail>Familial Amyloid Cardiomyopathy</Disease_Detail>
      <Disease_DB>FML097</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/familial_amyloid_cardiomyopathy?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hereditary Amyloidosis</Disease_Name>
      <Disease_Detail>Hereditary Amyloidosis</Disease_Detail>
      <Disease_DB>HRD039</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hereditary_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Fundus Albipunctatus</Disease_Name>
      <Disease_Detail>Fundus Albipunctatus</Disease_Detail>
      <Disease_DB>FND001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/fundus_albipunctatus?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Polyneuropathy</Disease_Name>
      <Disease_Detail>Polyneuropathy</Disease_Detail>
      <Disease_DB>PLY019</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/polyneuropathy?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Barth Syndrome</Disease_Name>
      <Disease_Detail>Barth Syndrome</Disease_Detail>
      <Disease_DB>BRT005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/barth_syndrome?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hypervitaminosis a</Disease_Name>
      <Disease_Detail>Hypervitaminosis a</Disease_Detail>
      <Disease_DB>HYP058</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hypervitaminosis_a?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Transthyretin Amyloidosis</Disease_Name>
      <Disease_Detail>Transthyretin Amyloidosis</Disease_Detail>
      <Disease_DB>TRN001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/transthyretin_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Superficial Siderosis</Disease_Name>
      <Disease_Detail>Superficial Siderosis</Disease_Detail>
      <Disease_DB>SPR066</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/superficial_siderosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Hyperthyroxinemia</Disease_Name>
      <Disease_Detail>Hyperthyroxinemia</Disease_Detail>
      <Disease_DB>HYP029</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/hyperthyroxinemia?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Carpal Tunnel Syndrome</Disease_Name>
      <Disease_Detail>Carpal Tunnel Syndrome</Disease_Detail>
      <Disease_DB>CRP001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/carpal_tunnel_syndrome?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Amyloid Neuropathy</Disease_Name>
      <Disease_Detail>Amyloid Neuropathy</Disease_Detail>
      <Disease_DB>AMY005</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/amyloid_neuropathy?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Atrophic Glossitis</Disease_Name>
      <Disease_Detail>Atrophic Glossitis</Disease_Detail>
      <Disease_DB>ATR073</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/atrophic_glossitis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Senile Systemic Amyloidosis</Disease_Name>
      <Disease_Detail>Senile Systemic Amyloidosis</Disease_Detail>
      <Disease_DB>SNL010</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/senile_systemic_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leptomeningeal Amyloidosis</Disease_Name>
      <Disease_Detail>Leptomeningeal Amyloidosis</Disease_Detail>
      <Disease_DB>LPT007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leptomeningeal_amyloidosis?search=TTR#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) complexed with(E)-3-(2-(trifluoromethyl)benzylideneaminooxy)propanoic acid (inhibitor 11)</PDB_Title>
      <PDB_ID>3GLZ</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GLZ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420152</ASD_Ligand>
      <PubMed_Title>Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>Plos One(2009)4:e6290-e6290</Journal>
      <PubMed_ID>19621084</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-17</PDB_Title>
      <PDB_ID>4ACT</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ACT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420184</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Inhibitors: Unique Mechanism of Negative-Cooperativity between Two T4 Binding Sites</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOMe</PDB_Title>
      <PDB_ID>3FC8</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FC8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420150</ASD_Ligand>
      <PubMed_Title>Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.</PubMed_Title>
      <Author>Mairal, T., et al.</Author>
      <Journal>Plos One(2009)4:e4124-e4124</Journal>
      <PubMed_ID>19125186</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS</PDB_Title>
      <PDB_ID>1FHN</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FHN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.</PubMed_Title>
      <Author>Sebastiao, M.P., et al.</Author>
      <Journal>J.Mol.Biol.(2001)306:733-744</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11243784?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURAL ASPECTS OF INOTROPIC BIPYRIDINE BINDING: CRYSTAL STRUCTURE DETERMINATION TO 1.9 ANGSTROMS OF THE HUMAN SERUM TRANSTHYRETIN-MILRINONE COMPLEX</PDB_Title>
      <PDB_ID>1TLM</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TLM</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420088</ASD_Ligand>
      <PubMed_Title>Structural aspects of inotropic bipyridine binding. Crystal structure determination to 1.9 A of the human serum transthyretin-milrinone complex.</PubMed_Title>
      <Author>Wojtczak, A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:6202-6206</Journal>
      <PubMed_ID>8454595</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION</PDB_Title>
      <PDB_ID>2TRY</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2TRY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.</PubMed_Title>
      <Author>Schormann, N., et al.</Author>
      <Journal>Amyloid(1998)5:175-187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9818054?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-7</PDB_Title>
      <PDB_ID>4AC2</PDB_ID>
      <Resolution>1.81</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AC2</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420182</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>22973437</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Transthyretin (wild-type)</PDB_Title>
      <PDB_ID>3A4D</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A4D</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Role of the Glutamic Acid 54 Residue in Transthyretin Stability and Thyroxine Binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN-V/122/I CARDIOMYOPATHIC MUTANT</PDB_Title>
      <PDB_ID>1TTR</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TTR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of the Val122Ile variant transthyretin - a cardiomyopathic mutant.</PubMed_Title>
      <Author>Damas, A.M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1996)52:966-972</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15299606?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with 3,5-diiodosalicylic acid</PDB_Title>
      <PDB_ID>3B56</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3B56</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01010031</ASD_Ligand>
      <PubMed_Title>Iodination of salicylic acid improves its binding to transthyretin</PubMed_Title>
      <Author>Gales, L., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2008)1784:512-517</Journal>
      <PubMed_ID>18155178</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Transthyretin mutant I84A at low pH</PDB_Title>
      <PDB_ID>2G3Z</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G3Z</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.</PubMed_Title>
      <Author>Pasquato, N., et al.</Author>
      <Journal>J.Mol.Biol.(2007)366:711-719</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17196219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human wild-type transthyretin in complex with diclofenac</PDB_Title>
      <PDB_ID>3CFQ</PDB_ID>
      <Resolution>2.09</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CFQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420139</ASD_Ligand>
      <PubMed_Title>Identification of a novel ligand binding motif in the transthyretin channel.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:100-110</Journal>
      <PubMed_ID>19954984</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN COMPLEX WITH RETINOIC ACID</PDB_Title>
      <PDB_ID>1TYR</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TYR</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05660009</ASD_Ligand>
      <PubMed_Title>Crystal structure of the transthyretin--retinoic-acid complex</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Eur.J.Biochem.(1995)234:563-569</Journal>
      <PubMed_ID>8536704</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the transthyretin mutant A108Y/L110E solved in space group p21212</PDB_Title>
      <PDB_ID>1SOK</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SOK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The beta-strand D of transthyretin trapped in two discrete conformations</PubMed_Title>
      <Author>Hornberg, A., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2004)1700:93-104</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15210129?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin in complex with indomethacin</PDB_Title>
      <PDB_ID>4IK7</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IK7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420203</ASD_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin in complex with indomethacin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzoic acid</PDB_Title>
      <PDB_ID>4L1T</PDB_ID>
      <Resolution>1.16</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4L1T</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420210</ASD_Ligand>
      <PubMed_Title>Fluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learn.</PubMed_Title>
      <Author>Baranczak, A., et al.</Author>
      <Journal>Biopolymers(2014)101:484-495</Journal>
      <PubMed_ID>24105107</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with iododiflunisal</PDB_Title>
      <PDB_ID>1Y1D</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Y1D</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420118</ASD_Ligand>
      <PubMed_Title>Human transthyretin in complex with iododiflunisal: structural features associated with a potent amyloid inhibitor.</PubMed_Title>
      <Author>Gales, L., et al.</Author>
      <Journal>Biochem.J.(2005)388:615-621</Journal>
      <PubMed_ID>15689188</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin mutant I84A at neutral pH</PDB_Title>
      <PDB_ID>2G4E</PDB_ID>
      <Resolution>2.17</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G4E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.</PubMed_Title>
      <Author>Pasquato, N., et al.</Author>
      <Journal>J.Mol.Biol.(2007)366:711-719</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17196219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)phenyl)propionamide</PDB_Title>
      <PDB_ID>4HJT</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HJT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420196</ASD_Ligand>
      <PubMed_Title>Stilbene vinyl sulfonamides as fluorogenic sensors of and traceless covalent kinetic stabilizers of transthyretin that prevent amyloidogenesis.</PubMed_Title>
      <Author>Suh, E.H., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:17869-17880</Journal>
      <PubMed_ID>24180271</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,6-dimethylbenzamide</PDB_Title>
      <PDB_ID>3ESN</PDB_ID>
      <Resolution>1.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ESN</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420147</ASD_Ligand>
      <PubMed_Title>Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:1115-1125</Journal>
      <PubMed_ID>19191553</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant L55P at acidic pH</PDB_Title>
      <PDB_ID>3DK0</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DK0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin in complex with 1-anilino-8-naphthalene sulfonate</PDB_Title>
      <PDB_ID>3CFN</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CFN</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD02210006</ASD_Ligand>
      <PubMed_Title>Identification of a novel ligand binding motif in the transthyretin channel.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:100-110</Journal>
      <PubMed_ID>19954984</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Wild type human transthyretin (TTR) complexed with GC-24 (TTRwt:GC-24)</PDB_Title>
      <PDB_ID>3NEO</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NEO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420166</ASD_Ligand>
      <PubMed_Title>The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2011)173:323-332</Journal>
      <PubMed_ID>20937391</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN THR119MET PROTEIN STABILISATION</PDB_Title>
      <PDB_ID>1F86</PDB_ID>
      <Resolution>1.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F86</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06898001</ASD_Ligand>
      <PubMed_Title>Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.</PubMed_Title>
      <Author>Sebastiao, M.P., et al.</Author>
      <Journal>J.Mol.Biol.(2001)306:733-744</Journal>
      <PubMed_ID>11243784</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with a covalent small molecule kinetic stabilizer</PDB_Title>
      <PDB_ID>3HJ0</PDB_ID>
      <Resolution>1.34</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3HJ0</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420156</ASD_Ligand>
      <PubMed_Title>Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>Nat.Chem.Biol.(2010)6:133-139</Journal>
      <PubMed_ID>20081815</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION</PDB_Title>
      <PDB_ID>1BZD</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BZD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.</PubMed_Title>
      <Author>Schormann, N., et al.</Author>
      <Journal>Amyloid(1998)5:175-187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9818054?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (also called prealbumin) complex with 3, 3',5,5'-tetraiodothyroacetic acid (t4ac)</PDB_Title>
      <PDB_ID>1Z7J</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1Z7J</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420119</ASD_Ligand>
      <PubMed_Title>Ligand binding at the transthyretin dimer-dimer interface: structure of the transthyretin-T4Ac complex at 2.2 Angstrom resolution.</PubMed_Title>
      <Author>Neumann, P., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:1313-1319</Journal>
      <PubMed_ID>16204882</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>V30M mutant human transthyretin (TTR) complexed with genistein (V30M:GEN) pH 7.5</PDB_Title>
      <PDB_ID>3KGT</PDB_ID>
      <Resolution>1.95</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KGT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03090008</ASD_Ligand>
      <PubMed_Title>Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2010)170:522-531</Journal>
      <PubMed_ID>20211733</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-2',3,3',4',5-Pentachlorobiphenyl</PDB_Title>
      <PDB_ID>2G9K</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G9K</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420130</ASD_Ligand>
      <PubMed_Title>Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity</PubMed_Title>
      <Author>Purkey, H.E., et al.</Author>
      <Journal>Chem.Biol.(2004)11:1719-1728</Journal>
      <PubMed_ID>15610856</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human Transthyretin (TTR) at pH 4.0</PDB_Title>
      <PDB_ID>3D7P</PDB_ID>
      <Resolution>1.72</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D7P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>J.Mol.Biol.(2008)382:1157-1167</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18662699?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION</PDB_Title>
      <PDB_ID>2TRH</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2TRH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.</PubMed_Title>
      <Author>Schormann, N., et al.</Author>
      <Journal>Amyloid(1998)5:175-187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9818054?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) complexed with 2-((3,5-dichloro-4-hydroxyphenyl)amino)benzoic acid</PDB_Title>
      <PDB_ID>3M1O</PDB_ID>
      <Resolution>1.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3M1O</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420165</ASD_Ligand>
      <PubMed_Title>Trapping of palindromic ligands within native transthyretin prevents amyloid formation.</PubMed_Title>
      <Author>Kolstoe, S.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:20483-20488</Journal>
      <PubMed_ID>21059958</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in Apo-form</PDB_Title>
      <PDB_ID>2QGB</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QGB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:260-270</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18095641?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Wild Type TTR Binding Apigenin (TTRwt:API)</PDB_Title>
      <PDB_ID>4DER</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DER</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420185</ASD_Ligand>
      <PubMed_Title>Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2012)180:143-153</Journal>
      <PubMed_ID>22842046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The Structure of V122I Mutant Transthyretin in Complex with AG10</PDB_Title>
      <PDB_ID>4HIQ</PDB_ID>
      <Resolution>1.18</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HIQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420193</ASD_Ligand>
      <PubMed_Title>AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.</PubMed_Title>
      <Author>Penchala, S.C., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2013)110:9992-9997</Journal>
      <PubMed_ID>23716704</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PDB_Title>
      <PDB_ID>4IKL</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IKL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420205</ASD_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN</PDB_Title>
      <PDB_ID>1DVQ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10742177?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with diflunisal at acidic pH</PDB_Title>
      <PDB_ID>4I89</PDB_ID>
      <Resolution>1.69</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I89</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01140129</ASD_Ligand>
      <PubMed_Title>Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs Lett.(2013)587:2325-2331</Journal>
      <PubMed_ID>23792159</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN TRANSTHYRETIN COMPLEXED WITH BROMOPHENOLS: A NEW MODE OF BINDING</PDB_Title>
      <PDB_ID>1E3F</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E3F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of Human Transthyretin Complexed with Bromophenols : A New Mode of Binding</PubMed_Title>
      <Author>Ghosh, M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1085</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10957627?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with Diflunisal analogues- TTR.2',4'-DICHLORO-4-HYDROXY-1,1'-BIPHENYL-3-CARBOXYLIC ACID</PDB_Title>
      <PDB_ID>2B77</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B77</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420123</ASD_Ligand>
      <PubMed_Title>Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.</PubMed_Title>
      <Author>Adamski-Werner, S.L., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:355-374</Journal>
      <PubMed_ID>14711308</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the transthyretin mutant TTR C10A/Y114C</PDB_Title>
      <PDB_ID>1IJN</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IJN</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Cys114-linked dimers of transthyretin are compatible with amyloid formation</PubMed_Title>
      <Author>Karlsson, A., et al.</Author>
      <Journal>Biochemistry(2005)44:13063-13070</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/16185074?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the apo form of human wild-type transthyretin</PDB_Title>
      <PDB_ID>3CFM</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CFM</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Identification of a novel ligand binding motif in the transthyretin channel.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:100-110</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19954984?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of V30M mutant human transthyretin complexed with glabridin</PDB_Title>
      <PDB_ID>4N87</PDB_ID>
      <Resolution>1.79</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4N87</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420212</ASD_Ligand>
      <PubMed_Title>Crystal structures of human transthyretin complexed with glabridin</PubMed_Title>
      <Author>Yokoyama, T., et al.</Author>
      <Journal>J.Med.Chem.(2014)57:1090-1096</Journal>
      <PubMed_ID>24422526</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dichlorostyryl)phenol</PDB_Title>
      <PDB_ID>3IMR</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMR</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420157</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the F87M/L110M mutant of human transthyretin at pH 5.5</PDB_Title>
      <PDB_ID>3GPS</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GPS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.</PubMed_Title>
      <Author>Palmieri, L.de.C., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:31731-31741</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20659897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromoaniline</PDB_Title>
      <PDB_ID>3IMV</PDB_ID>
      <Resolution>1.47</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420161</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH 3',5'-DINITRO-N-ACETYL-L-THYRONINE</PDB_Title>
      <PDB_ID>2ROY</PDB_ID>
      <Resolution>2.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ROY</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420136</ASD_Ligand>
      <PubMed_Title>Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution.</PubMed_Title>
      <Author>Wojtczak, A., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1996)52:758-765</Journal>
      <PubMed_ID>15299640</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4-hydroxy-3,3',5,4'-tetrachlorobiphenyl</PDB_Title>
      <PDB_ID>2GAB</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2GAB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420131</ASD_Ligand>
      <PubMed_Title>Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity</PubMed_Title>
      <Author>Purkey, H.E., et al.</Author>
      <Journal>Chem.Biol.(2004)11:1719-1728</Journal>
      <PubMed_ID>15610856</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) Complexed with Hydroxylated polychlorinated Biphenyl-4,4'-dihydroxy-3,3',5,5'-tetrachlorobiphenyl</PDB_Title>
      <PDB_ID>2G5U</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G5U</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420129</ASD_Ligand>
      <PubMed_Title>Hydroxylated polychlorinated biphenyls selectively bind transthyretin in blood and inhibit amyloidogenesis: rationalizing rodent PCB toxicity</PubMed_Title>
      <Author>Purkey, H.E., et al.</Author>
      <Journal>Chem.Biol.(2004)11:1719-1728</Journal>
      <PubMed_ID>15610856</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in complex with N-(3,5-Dibromo-4-hydroxyphenyl)benzamide</PDB_Title>
      <PDB_ID>3CN4</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CN4</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420145</ASD_Ligand>
      <PubMed_Title>Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:6348-6358</Journal>
      <PubMed_ID>18811132</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RETINOL BINDING PROTEIN COMPLEXED WITH TRANSTHYRETIN</PDB_Title>
      <PDB_ID>1RLB</PDB_ID>
      <Resolution>3.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1RLB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein.</PubMed_Title>
      <Author>Monaco, H.L., et al.</Author>
      <Journal>Science(1995)268:1039-1041</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/7754382?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-1</PDB_Title>
      <PDB_ID>4ABQ</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ABQ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420178</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>22973437</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MECHANISM OF MOLECULAR RECOGNITION. STRUCTURAL ASPECTS OF 3,3'-DIIODO-L-THYRONINE BINDING TO HUMAN SERUM TRANSTHYRETIN</PDB_Title>
      <PDB_ID>1THA</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1THA</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420082</ASD_Ligand>
      <PubMed_Title>Mechanism of molecular recognition. Structural aspects of 3,3'-diiodo-L-thyronine binding to human serum transthyretin.</PubMed_Title>
      <Author>Wojtczak, A., et al.</Author>
      <Journal>J.Biol.Chem.(1992)267:353-357</Journal>
      <PubMed_ID>1730601</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE HIGHLY AMYLOIDOGENIC TRANSTHYRETIN MUTANT TTR G53S/E54D/L55S</PDB_Title>
      <PDB_ID>1G1O</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1G1O</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The beta-slip: a novel concept in transthyretin amyloidosis.</PubMed_Title>
      <Author>Eneqvist, T., et al.</Author>
      <Journal>Mol.Cell(2000)6:1207-1218</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11106758?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 2-(3,5-Dimethylphenyl)benzoxazole</PDB_Title>
      <PDB_ID>2QGE</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QGE</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420134</ASD_Ligand>
      <PubMed_Title>Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:260-270</Journal>
      <PubMed_ID>18095641</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH RESVERATROL</PDB_Title>
      <PDB_ID>1DVS</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD05250001</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichlorophenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide</PDB_Title>
      <PDB_ID>4FI6</PDB_ID>
      <Resolution>1.46</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4FI6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420190</ASD_Ligand>
      <PubMed_Title>Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate.</PubMed_Title>
      <Author>Grimster, N.P., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:5656-5668</Journal>
      <PubMed_ID>23350654</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30--&gt;MET VARIANT TO 1.7 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1ETA</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ETA</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06898001</ASD_Ligand>
      <PubMed_Title>The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30--&gt;Met variant to 1.7-A resolution.</PubMed_Title>
      <Author>Hamilton, J.A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:2416-2424</Journal>
      <PubMed_ID>8428915</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of wild-type TTR in complex with tafamidis</PDB_Title>
      <PDB_ID>3TCT</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TCT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420194</ASD_Ligand>
      <PubMed_Title>Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.</PubMed_Title>
      <Author>Bulawa, C.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2012)109:9629-9634</Journal>
      <PubMed_ID>22645360</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (4 carbon linker)</PDB_Title>
      <PDB_ID>2FBR</PDB_ID>
      <Resolution>1.46</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FBR</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420127</ASD_Ligand>
      <PubMed_Title>Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.</PubMed_Title>
      <Author>Green, N.S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2003)125:13404-13414</Journal>
      <PubMed_ID>14583036</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant Y114H at acidic pH</PDB_Title>
      <PDB_ID>3DK2</PDB_ID>
      <Resolution>2.35</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DK2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>COMPLEX OF TTR AND RBP4 AND OLEIC ACID</PDB_Title>
      <PDB_ID>2WQA</PDB_ID>
      <Resolution>2.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2WQA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal Structure of Rbp4 Bound to Linoleic Acid and Ttr</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin in complex with 1-amino-5-naphthalene sulfonate</PDB_Title>
      <PDB_ID>3CFT</PDB_ID>
      <Resolution>1.87</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CFT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420140</ASD_Ligand>
      <PubMed_Title>Identification of a novel ligand binding motif in the transthyretin channel.</PubMed_Title>
      <Author>Lima, L.M., et al.</Author>
      <Journal>Bioorg.Med.Chem.(2010)18:100-110</Journal>
      <PubMed_ID>19954984</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin variant A25T - #1</PDB_Title>
      <PDB_ID>3I9A</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I9A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin variant A25T - #1</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystallographic study of novel transthyretin ligands exhibiting negative-cooperativity between two T4 binding sites.</PDB_Title>
      <PDB_ID>4ANK</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ANK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22973437?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DIBENZOFURAN-4,6-DICARBOXYLIC ACID</PDB_Title>
      <PDB_ID>1DVU</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420050</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN TRANSTHYRETIN COMPLEXED WITH BROMOPHENOLS: A NEW MODE OF BINDING</PDB_Title>
      <PDB_ID>1E4H</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E4H</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420060</ASD_Ligand>
      <PubMed_Title>Structure of Human Transthyretin Complexed with Bromophenols : A New Mode of Binding</PubMed_Title>
      <Author>Ghosh, M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1085</Journal>
      <PubMed_ID>10957627</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of Human Transthyretin (E54K)</PDB_Title>
      <PDB_ID>3A4F</PDB_ID>
      <Resolution>1.99</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A4F</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Role of the Glutamic Acid 54 Residue in Transthyretin Stability and Thyroxine Binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>V30M mutant human transthyretin (TTR) complexed with GC-24 (V30M:GC-24)</PDB_Title>
      <PDB_ID>3NEX</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NEX</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420166</ASD_Ligand>
      <PubMed_Title>The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2011)173:323-332</Journal>
      <PubMed_ID>20937391</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN (DEL VAL122)</PDB_Title>
      <PDB_ID>1BZ8</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BZ8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural Analysis of Delval122 Transthyretin-A Deletion Mutant</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin in complex with indomethacin</PDB_Title>
      <PDB_ID>4IKI</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IKI</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420203</ASD_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin in complex with indomethacin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (11 carbon linker).</PDB_Title>
      <PDB_ID>3IPB</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420163</ASD_Ligand>
      <PubMed_Title>Trapping of palindromic ligands within native transthyretin prevents amyloid formation.</PubMed_Title>
      <Author>Kolstoe, S.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:20483-20488</Journal>
      <PubMed_ID>21059958</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinetic stabilization of transthyretin through covalent modification of K15 by (E)-N-(4-(4-hydroxy-3,5-dimethylstyryl)ethanesulfonamide</PDB_Title>
      <PDB_ID>4HJS</PDB_ID>
      <Resolution>1.22</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HJS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420195</ASD_Ligand>
      <PubMed_Title>Stilbene vinyl sulfonamides as fluorogenic sensors of and traceless covalent kinetic stabilizers of transthyretin that prevent amyloidogenesis.</PubMed_Title>
      <Author>Suh, E.H., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:17869-17880</Journal>
      <PubMed_ID>24180271</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>V30M mutant human transthyretin (TTR) complexed with GC-1 (V30M:GC-1)</PDB_Title>
      <PDB_ID>3NES</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NES</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420167</ASD_Ligand>
      <PubMed_Title>The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2011)173:323-332</Journal>
      <PubMed_ID>20937391</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with iododiflunisal-betaAlaOH</PDB_Title>
      <PDB_ID>3FCB</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3FCB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420151</ASD_Ligand>
      <PubMed_Title>Iodine atoms: a new molecular feature for the design of potent transthyretin fibrillogenesis inhibitors.</PubMed_Title>
      <Author>Mairal, T., et al.</Author>
      <Journal>Plos One(2009)4:e4124-e4124</Journal>
      <PubMed_ID>19125186</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 2-(3,5-Dimethyl-4-hydroxyphenyl)benzoxazole</PDB_Title>
      <PDB_ID>2QGC</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QGC</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420132</ASD_Ligand>
      <PubMed_Title>Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:260-270</Journal>
      <PubMed_ID>18095641</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant L58H at acidic pH</PDB_Title>
      <PDB_ID>3DJS</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of 2,4-dinitrophenol in complex with human transthyretin</PDB_Title>
      <PDB_ID>2B15</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B15</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420120</ASD_Ligand>
      <PubMed_Title>The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin</PubMed_Title>
      <Author>Morais-de-Sa, E., et al.</Author>
      <Journal>ACTA CRYSTALLOGR.,SECT.D(2006)62:512-519</Journal>
      <PubMed_ID>16627944</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin - wild type</PDB_Title>
      <PDB_ID>3I9P</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I9P</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin - wild type</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in complex with 3,5-Dimethyl-4-hydroxystilbene</PDB_Title>
      <PDB_ID>3CN0</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CN0</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420141</ASD_Ligand>
      <PubMed_Title>Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:6348-6358</Journal>
      <PubMed_ID>18811132</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Wild type human transthyretin (TTR) complexed with genistein (TTRwt:GEN) pH 7.5</PDB_Title>
      <PDB_ID>3KGU</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KGU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD03090008</ASD_Ligand>
      <PubMed_Title>Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2010)170:522-531</Journal>
      <PubMed_ID>20211733</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6 soaked</PDB_Title>
      <PDB_ID>3DID</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DID</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.</PubMed_Title>
      <Author>Palmieri, L.de.C., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:31731-31741</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20659897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH N-(M-TRIFLUOROMETHYLPHENYL) PHENOXAZINE-4,6-DICARBOXYLIC ACID</PDB_Title>
      <PDB_ID>1DVY</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVY</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420055</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN VARIANT L58H at neutral pH</PDB_Title>
      <PDB_ID>3DJR</PDB_ID>
      <Resolution>2.02</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin</PDB_Title>
      <PDB_ID>3W3B</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3W3B</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The Structure of V122I Mutant Transthyretin in Complex with Tafamidis</PDB_Title>
      <PDB_ID>4HIS</PDB_ID>
      <Resolution>1.2</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HIS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420194</ASD_Ligand>
      <PubMed_Title>AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.</PubMed_Title>
      <Author>Penchala, S.C., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2013)110:9992-9997</Journal>
      <PubMed_ID>23716704</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1,1'-biphenyl]-4,4'diol</PDB_Title>
      <PDB_ID>4MAS</PDB_ID>
      <Resolution>1.22</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4MAS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420129</ASD_Ligand>
      <PubMed_Title>High Resolution Structure of Wild Type Human Transthyretin in Complex with 3,3',5,5'-tetrachloro-[1,1'-biphenyl]-4,4'diol</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1TTA</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TTA</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30--&gt;Met variant to 1.7-A resolution.</PubMed_Title>
      <Author>Hamilton, J.A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:2416-2424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8428915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL 30--&gt;MET VARIANT TO 1.7 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1ETB</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ETB</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06898001</ASD_Ligand>
      <PubMed_Title>The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30--&gt;Met variant to 1.7-A resolution.</PubMed_Title>
      <Author>Hamilton, J.A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:2416-2424</Journal>
      <PubMed_ID>8428915</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF HUMAN TRANSTHYRETIN COMPLEXED WITH BROMOPHENOLS: A NEW MODE OF BINDING</PDB_Title>
      <PDB_ID>1E5A</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1E5A</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of Human Transthyretin Complexed with Bromophenols : A New Mode of Binding</PubMed_Title>
      <Author>Ghosh, M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2000)56:1085</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10957627?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Covalent modification of transthyretin K15 by yielding the fluorescent conjugate (E)-3-(dimethylamino)-5-(4-hydroxy-3,5-dimethylstyryl)benzamide</PDB_Title>
      <PDB_ID>4L1S</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4L1S</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420209</ASD_Ligand>
      <PubMed_Title>Fluorogenic small molecules requiring reaction with a specific protein to create a fluorescent conjugate for biological imaging-what we know and what we need to learn.</PubMed_Title>
      <Author>Baranczak, A., et al.</Author>
      <Journal>Biopolymers(2014)101:484-495</Journal>
      <PubMed_ID>24105107</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant Y114H</PDB_Title>
      <PDB_ID>3CXF</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CXF</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs J.(2008)275:5841-5854</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19021760?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-4-(4-aminostyryl)-2,6-dibromophenol</PDB_Title>
      <PDB_ID>3IMT</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420159</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (3,4-dihydroxy-5-nitrophenyl)(2-fluorophenyl)methanone</PDB_Title>
      <PDB_ID>3P3R</PDB_ID>
      <Resolution>1.25</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P3R</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420173</ASD_Ligand>
      <PubMed_Title>Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.</PubMed_Title>
      <Author>Alhamadsheh, M.M., et al.</Author>
      <Journal>Sci Transl Med(2011)3:97ra81-97ra81</Journal>
      <PubMed_ID>21865539</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Cys10 sulfonated transthyretin</PDB_Title>
      <PDB_ID>2H4E</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2H4E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural basis for the protective role of sulfite against transthyretin amyloid formation.</PubMed_Title>
      <Author>Gales, L., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2007)1774:59-64</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17175208?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN (ALSO CALLED PREALBUMIN) COMPLEX WITH THYROXINE (T4)</PDB_Title>
      <PDB_ID>2ROX</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ROX</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06898001</ASD_Ligand>
      <PubMed_Title>Structures of human transthyretin complexed with thyroxine at 2.0 A resolution and 3',5'-dinitro-N-acetyl-L-thyronine at 2.2 A resolution.</PubMed_Title>
      <Author>Wojtczak, A., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(1996)52:758-765</Journal>
      <PubMed_ID>15299640</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT CRYO TEMPERATURE</PDB_Title>
      <PDB_ID>1IIK</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1IIK</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Disulfide-Bond Formation in the Transthyretin Mutant Y114C Prevents Amyloid Fibril Formation in Vivo and in Vitro</PubMed_Title>
      <Author>Eneqvist, T., et al.</Author>
      <Journal>Biochemistry(2002)41:13143-13151</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12403615?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinetic Stabilization of transthyretin through covalent modification of K15 by 3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide</PDB_Title>
      <PDB_ID>4FI7</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4FI7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420191</ASD_Ligand>
      <PubMed_Title>Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate.</PubMed_Title>
      <Author>Grimster, N.P., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:5656-5668</Journal>
      <PubMed_ID>23350654</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin complexed with glabridin</PDB_Title>
      <PDB_ID>4N86</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4N86</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420212</ASD_Ligand>
      <PubMed_Title>Crystal structures of human transthyretin complexed with glabridin</PubMed_Title>
      <Author>Yokoyama, T., et al.</Author>
      <Journal>J.Med.Chem.(2014)57:1090-1096</Journal>
      <PubMed_ID>24422526</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>X-ray crystal structure of human Transthyretin at room temperature</PDB_Title>
      <PDB_ID>3U2I</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3U2I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Hydrogen-bond network and pH sensitivity in transthyretin: Neutron crystal structure of human transthyretin</PubMed_Title>
      <Author>Yokoyama, T., et al.</Author>
      <Journal>J.Struct.Biol.(2012)177:283-290</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22248451?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Human Transthyretin (E54G)</PDB_Title>
      <PDB_ID>3A4E</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3A4E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Role of the Glutamic Acid 54 Residue in Transthyretin Stability and Thyroxine Binding</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Tyr78Phe</PDB_Title>
      <PDB_ID>2B16</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B16</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420120</ASD_Ligand>
      <PubMed_Title>The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin</PubMed_Title>
      <Author>Morais-de-Sa, E., et al.</Author>
      <Journal>ACTA CRYSTALLOGR.,SECT.D(2006)62:512-519</Journal>
      <PubMed_ID>16627944</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of transthyretin L55P in complex with Zn</PDB_Title>
      <PDB_ID>3SSG</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3SSG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insights into a zinc-dependent pathway leading to Leu55Pro transthyretin amyloid fibrils.</PubMed_Title>
      <Author>Castro-Rodrigues, A.F., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2011)67:1035-1044</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22120741?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of Transthyretin mutant I84S at acidic pH</PDB_Title>
      <PDB_ID>2G3X</PDB_ID>
      <Resolution>1.58</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G3X</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.</PubMed_Title>
      <Author>Pasquato, N., et al.</Author>
      <Journal>J.Mol.Biol.(2007)366:711-719</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17196219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>transthyretin with tethered inhibitor on one monomer.</PDB_Title>
      <PDB_ID>1U21</PDB_ID>
      <Resolution>1.69</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1U21</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420106</ASD_Ligand>
      <PubMed_Title>Kinetic stabilization of an oligomeric protein by a single ligand binding event</PubMed_Title>
      <Author>Wiseman, R.L., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2005)127:5540-5551</Journal>
      <PubMed_ID>15826192</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin mutant I84S at PH 7.5</PDB_Title>
      <PDB_ID>2NOY</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2NOY</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin</PubMed_Title>
      <Author>Pasquato, N., et al.</Author>
      <Journal>J.Mol.Biol.(2007)366:711-719</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17196219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Wild Type TTR Binding Kaempferol (TTRwt:KAE)</PDB_Title>
      <PDB_ID>4DET</PDB_ID>
      <Resolution>2.05</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DET</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD11030079</ASD_Ligand>
      <PubMed_Title>Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2012)180:143-153</Journal>
      <PubMed_ID>22842046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The orthorhombic crystal structure of transthyretin in complex with diethylstilbestrol</PDB_Title>
      <PDB_ID>1TT6</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TT6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01240003</ASD_Ligand>
      <PubMed_Title>The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors</PubMed_Title>
      <Author>Morais-de-Sa, E., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:53483-53490</Journal>
      <PubMed_ID>15469931</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF THE TRANSTHYRETIN MUTANT TTR Y114C-DATA COLLECTED AT ROOM TEMPERATURE</PDB_Title>
      <PDB_ID>1III</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1III</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Disulfide-Bond Formation in the Transthyretin Mutant Y114C Prevents Amyloid Fibril Formation in Vivo and in Vitro</PubMed_Title>
      <Author>Eneqvist, T., et al.</Author>
      <Journal>Biochemistry(2002)41:13143-13151</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/12403615?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-18</PDB_Title>
      <PDB_ID>4AC4</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4AC4</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420183</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Inhibitors: Unique Mechanism of Negative-Cooperativity between Two T4 Binding Sites</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Wild Type TTR Binding Chrysin (TTRwt:CHR)</PDB_Title>
      <PDB_ID>4DES</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DES</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01328023</ASD_Ligand>
      <PubMed_Title>Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2012)180:143-153</Journal>
      <PubMed_ID>22842046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant V20S</PDB_Title>
      <PDB_ID>3BT0</PDB_ID>
      <Resolution>1.59</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BT0</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs J.(2008)275:5841-5854</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19021760?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the F87M/L110M mutant of human transthyretin at pH 4.6</PDB_Title>
      <PDB_ID>3DGD</PDB_ID>
      <Resolution>1.38</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DGD</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.</PubMed_Title>
      <Author>Palmieri, L.de.C., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:31731-31741</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20659897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION</PDB_Title>
      <PDB_ID>1TSH</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TSH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.</PubMed_Title>
      <Author>Schormann, N., et al.</Author>
      <Journal>Amyloid(1998)5:175-187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9818054?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH O-TRIFLUOROMETHYLPHENYL ANTHRANILIC ACID</PDB_Title>
      <PDB_ID>1DVZ</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVZ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420059</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 2-(3,5-Dibromo-4-hydroxyphenyl)benzoxazole</PDB_Title>
      <PDB_ID>2QGD</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QGD</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420133</ASD_Ligand>
      <PubMed_Title>Biochemical and structural evaluation of highly selective 2-arylbenzoxazole-based transthyretin amyloidogenesis inhibitors.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:260-270</Journal>
      <PubMed_ID>18095641</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN AT 1.5A RESOLUTION</PDB_Title>
      <PDB_ID>1F41</PDB_ID>
      <Resolution>1.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1F41</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>A comparative analysis of 23 structures of the amyloidogenic protein transthyretin.</PubMed_Title>
      <Author>Hornberg, A., et al.</Author>
      <Journal>J.Mol.Biol.(2000)302:649-669</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10986125?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>STRUCTURE OF PREALBUMIN, SECONDARY, TERTIARY AND QUATERNARY INTERACTIONS DETERMINED BY FOURIER REFINEMENT AT 1.8 ANGSTROMS</PDB_Title>
      <PDB_ID>2PAB</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2PAB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A.</PubMed_Title>
      <Author>Blake, C.C., et al.</Author>
      <Journal>J.Mol.Biol.(1978)121:339-356</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/671542?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 3-(9H-fluoren-9-ylideneaminooxy)propanoic acid (inhibitor 15)</PDB_Title>
      <PDB_ID>3GS4</PDB_ID>
      <Resolution>1.78</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GS4</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420154</ASD_Ligand>
      <PubMed_Title>Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>Plos One(2009)4:e6290-e6290</Journal>
      <PubMed_ID>19621084</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with (S)-3-(9H-fluoren-9-ylideneaminooxy)-2-methylpropanoic acid (inhibitor 16)</PDB_Title>
      <PDB_ID>3GS0</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GS0</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420153</ASD_Ligand>
      <PubMed_Title>Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>Plos One(2009)4:e6290-e6290</Journal>
      <PubMed_ID>19621084</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human Transthyretin with bound iodide</PDB_Title>
      <PDB_ID>1ZCR</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZCR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The effect of iodide and chloride on transthyretin structure and stability</PubMed_Title>
      <Author>Hornberg, A., et al.</Author>
      <Journal>Biochemistry(2005)44:9290-9299</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15981995?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with Benzoxazole</PDB_Title>
      <PDB_ID>2F8I</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F8I</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420126</ASD_Ligand>
      <PubMed_Title>Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action</PubMed_Title>
      <Author>Razavi, H., et al.</Author>
      <Journal>Angew.Chem.Int.Ed.Engl.(2003)42:2758-2761</Journal>
      <PubMed_ID>12820260</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-2,5-dichlorobenzamide</PDB_Title>
      <PDB_ID>3ESO</PDB_ID>
      <Resolution>1.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ESO</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420148</ASD_Ligand>
      <PubMed_Title>Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:1115-1125</Journal>
      <PubMed_ID>19191553</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TRANSTHYRETIN STABILITY AS A KEY FACTOR IN AMYLOIDOGENESIS</PDB_Title>
      <PDB_ID>1FH2</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1FH2</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Transthyretin stability as a key factor in amyloidogenesis: X-ray analysis at atomic resolution.</PubMed_Title>
      <Author>Sebastiao, M.P., et al.</Author>
      <Journal>J.Mol.Biol.(2001)306:733-744</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11243784?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>TERTIARY STRUCTURES OF THREE AMYLOIDOGENIC TRANSTHYRETIN VARIANTS AND IMPLICATIONS FOR AMYLOID FIBRIL FORMATION</PDB_Title>
      <PDB_ID>1BZE</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BZE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Tertiary structures of amyloidogenic and non-amyloidogenic transthyretin variants: new model for amyloid fibril formation.</PubMed_Title>
      <Author>Schormann, N., et al.</Author>
      <Journal>Amyloid(1998)5:175-187</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9818054?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with bivalant amyloid inhibitor (6 carbon linker)</PDB_Title>
      <PDB_ID>2FLM</PDB_ID>
      <Resolution>1.65</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2FLM</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420128</ASD_Ligand>
      <PubMed_Title>Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.</PubMed_Title>
      <Author>Green, N.S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2003)125:13404-13414</Journal>
      <PubMed_ID>14583036</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxybiphenyl</PDB_Title>
      <PDB_ID>3CN2</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CN2</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420143</ASD_Ligand>
      <PubMed_Title>Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:6348-6358</Journal>
      <PubMed_ID>18811132</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PDB_Title>
      <PDB_ID>4IKK</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IKK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420205</ASD_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the highly amyloidogenic transthyretin mutant TTR G53S/E54D/L55S- heated protein</PDB_Title>
      <PDB_ID>2QEL</PDB_ID>
      <Resolution>2.29</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2QEL</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Heating of proteins as a means of improving crystallization: a successful case study on a highly amyloidogenic triple mutant of human transthyretin</PubMed_Title>
      <Author>Karlsson, A., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.F(2007)63:695-700</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17671371?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant V30M at acidic pH</PDB_Title>
      <PDB_ID>3DJT</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with the fluorescent folding sensor (E)-7-hydroxy-3-(4-hydroxy-3,5-dimethylstyryl)-4-methyl-2H-chromen-2-one</PDB_Title>
      <PDB_ID>4KY2</PDB_ID>
      <Resolution>1.13</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4KY2</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420208</ASD_Ligand>
      <PubMed_Title>Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors.</PubMed_Title>
      <Author>Myung, N., et al.</Author>
      <Journal>Chem.Commun.(Camb.)(2013)49:9188-9190</Journal>
      <PubMed_ID>23989101</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of TTR variant I84S in complex with CHF5074 at acidic pH</PDB_Title>
      <PDB_ID>4I87</PDB_ID>
      <Resolution>1.69</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I87</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420198</ASD_Ligand>
      <PubMed_Title>Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs Lett.(2013)587:2325-2331</Journal>
      <PubMed_ID>23792159</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human Transthyretin (TTR) at pH3.5</PDB_Title>
      <PDB_ID>3CBR</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CBR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural insight into pH-induced conformational changes within the native human transthyretin tetramer.</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>J.Mol.Biol.(2008)382:1157-1167</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/18662699?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The structure of human retinol binding protein with its carrier protein transthyretin reveals interaction with the carboxy terminus of RBP</PDB_Title>
      <PDB_ID>1QAB</PDB_ID>
      <Resolution>3.2</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QAB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The structure of human retinol-binding protein (RBP) with its carrier protein transthyretin reveals an interaction with the carboxy terminus of RBP.</PubMed_Title>
      <Author>Naylor, H.M., et al.</Author>
      <Journal>Biochemistry(1999)38:2647-2653</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/10052934?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with diflunisal analogues- TTR.3',5'-difluorobiphenyl-4-carboxylic acid</PDB_Title>
      <PDB_ID>2B9A</PDB_ID>
      <Resolution>1.54</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B9A</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420124</ASD_Ligand>
      <PubMed_Title>Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of Amyloidogenesis.</PubMed_Title>
      <Author>Adamski-Werner, S.L., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:355-374</Journal>
      <PubMed_ID>14711308</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-6</PDB_Title>
      <PDB_ID>4ABW</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ABW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420181</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>22973437</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Wild Type TTR Binding Naringenin (TTRwt:NAR)</PDB_Title>
      <PDB_ID>4DEU</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DEU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420188</ASD_Ligand>
      <PubMed_Title>Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2012)180:143-153</Journal>
      <PubMed_ID>22842046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with 2,6-dibromo-4-(2,6-dichlorophenethyl)phenol</PDB_Title>
      <PDB_ID>3IMS</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMS</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420158</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>LEU 55 PRO TRANSTHYRETIN CRYSTAL STRUCTURE</PDB_Title>
      <PDB_ID>5TTR</PDB_ID>
      <Resolution>2.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=5TTR</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of amyloidogenic Leu55 --&gt; Pro transthyretin variant reveals a possible pathway for transthyretin polymerization into amyloid fibrils.</PubMed_Title>
      <Author>Sebastiao, M.P., et al.</Author>
      <Journal>J.Biol.Chem.(1998)273:24715-24722</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9733771?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the transthyretin-retinol binding protein-Fab complex</PDB_Title>
      <PDB_ID>3BSZ</PDB_ID>
      <Resolution>3.38</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3BSZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structural and mutational analyses of protein-protein interactions between transthyretin and retinol-binding protein.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs J.(2008)275:5841-5854</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/19021760?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin natural mutant A25T</PDB_Title>
      <PDB_ID>3TFB</PDB_ID>
      <Resolution>2.03</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3TFB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Dissecting the Structure, Thermodynamic Stability, and Aggregation Properties of the A25T Transthyretin (A25T-TTR) Variant Involved in Leptomeningeal Amyloidosis: Identifying Protein Partners That Co-Aggregate during A25T-TTR Fibrillogenesis in Cerebrospinal Fluid.</PubMed_Title>
      <Author>Azevedo, E.P., et al.</Author>
      <Journal>Biochemistry(2011)50:11070-11083</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22091638?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin in complex with CHF5074 at neutral pH</PDB_Title>
      <PDB_ID>4I85</PDB_ID>
      <Resolution>1.67</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I85</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420198</ASD_Ligand>
      <PubMed_Title>Structural evidence for native state stabilization of a conformationally labile amyloidogenic transthyretin variant by fibrillogenesis inhibitors.</PubMed_Title>
      <Author>Zanotti, G., et al.</Author>
      <Journal>Febs Lett.(2013)587:2325-2331</Journal>
      <PubMed_ID>23792159</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of the Wild Type TTR Binding Luteolin (TTRwt:LUT)</PDB_Title>
      <PDB_ID>4DEW</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4DEW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420189</ASD_Ligand>
      <PubMed_Title>Flavonoid interactions with human transthyretin: Combined structural and thermodynamic analysis.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2012)180:143-153</Journal>
      <PubMed_ID>22842046</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin in complex with lumiracoxib</PDB_Title>
      <PDB_ID>4IIZ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IIZ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420201</ASD_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin in complex with lumiracoxib</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin variant A25T - #2</PDB_Title>
      <PDB_ID>3I9I</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3I9I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin variant A25T - #2</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-2</PDB_Title>
      <PDB_ID>4ABU</PDB_ID>
      <Resolution>1.86</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ABU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420179</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>22973437</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human Transthyretin (TTR) complexed with a palindromic bivalent amyloid inhibitor (7 carbon linker).</PDB_Title>
      <PDB_ID>3IPE</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IPE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Trapping of palindromic ligands within native transthyretin prevents amyloid formation.</PubMed_Title>
      <Author>Kolstoe, S.E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(2010)107:20483-20488</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21059958?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN TRANSTHYRETIN (PREALBUMIN)</PDB_Title>
      <PDB_ID>1BMZ</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BMZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.</PubMed_Title>
      <Author>Peterson, S.A., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1998)95:12956-12960</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/9789022?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin with bound chloride</PDB_Title>
      <PDB_ID>1ZD6</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ZD6</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The effect of iodide and chloride on transthyretin structure and stability</PubMed_Title>
      <Author>Hornberg, A., et al.</Author>
      <Journal>Biochemistry(2005)44:9290-9299</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15981995?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (ttr) complexed with diflunisal</PDB_Title>
      <PDB_ID>3D2T</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3D2T</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD01140129</ASD_Ligand>
      <PubMed_Title>Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis.</PubMed_Title>
      <Author>Adamski-Werner, S.L., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:355-374</Journal>
      <PubMed_ID>14711308</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The X-ray crystallographic structure of the amyloidogenic variant TTR Tyr78Phe</PDB_Title>
      <PDB_ID>1X7S</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1X7S</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis.</PubMed_Title>
      <Author>Neto-Silva, R.M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:333-339</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15735344?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin at pH 4.6</PDB_Title>
      <PDB_ID>2G4G</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2G4G</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Acidic pH-induced conformational changes in amyloidogenic mutant transthyretin.</PubMed_Title>
      <Author>Pasquato, N., et al.</Author>
      <Journal>J.Mol.Biol.(2007)366:711-719</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/17196219?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1TTB</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TTB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30--&gt;Met variant to 1.7-A resolution.</PubMed_Title>
      <Author>Hamilton, J.A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:2416-2424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8428915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PDB_Title>
      <PDB_ID>4IKJ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IKJ</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420205</ASD_Ligand>
      <PubMed_Title>Crystal structure of wild-type human transthyretin in complex with sulindac</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal Structure of V30M transthyretin complexed with (-)-epigallocatechin gallate (EGCG)</PDB_Title>
      <PDB_ID>3NG5</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NG5</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD04320001</ASD_Ligand>
      <PubMed_Title>Crystal structure of green tea polyphenol(-)-epigallocatechin gallate (EGCG)-transthyretin complex reveals novel binding site distinct from thyroxine binding site</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 5-(2-ethoxyphenyl)-3-(pyridin-4-yl)-1,2,4-oxadiazole</PDB_Title>
      <PDB_ID>3P3U</PDB_ID>
      <Resolution>1.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P3U</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420176</ASD_Ligand>
      <PubMed_Title>Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.</PubMed_Title>
      <Author>Alhamadsheh, M.M., et al.</Author>
      <Journal>Sci Transl Med(2011)3:97ra81-97ra81</Journal>
      <PubMed_ID>21865539</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant L55P at neutral pH</PDB_Title>
      <PDB_ID>3DJZ</PDB_ID>
      <Resolution>1.82</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DJZ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4)</PDB_Title>
      <PDB_ID>3OZK</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OZK</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06898001</ASD_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin variant A25T in complex with thyroxine (T4)</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the F87M/L110M mutant of human transthyretin at pH 6.5</PDB_Title>
      <PDB_ID>3GRB</PDB_ID>
      <Resolution>1.75</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GRB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.</PubMed_Title>
      <Author>Palmieri, L.de.C., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:31731-31741</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20659897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with diflunisal analogues- TTR. 2',6'-Difluorobiphenyl-4-carboxylic Acid</PDB_Title>
      <PDB_ID>2F7I</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2F7I</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420125</ASD_Ligand>
      <PubMed_Title>Diflunisal Analogues Stabilize the Native State of Transthyretin. Potent Inhibition of Amyloidogenesis.</PubMed_Title>
      <Author>Adamski-Werner, S.L., et al.</Author>
      <Journal>J.Med.Chem.(2004)47:355-374</Journal>
      <PubMed_ID>14711308</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE DETERMINATION AT 2.3A OF HUMAN TRANSTHYRETIN-3',5'-DIBROMO-2',4,4',6-TETRA-HYDROXYAURONE COMPLEX</PDB_Title>
      <PDB_ID>1THC</PDB_ID>
      <Resolution>2.3</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1THC</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420084</ASD_Ligand>
      <PubMed_Title>Crystal structure determination at 2.3-A resolution of human transthyretin-3',5'-dibromo-2',4,4',6-tetrahydroxyaurone complex.</PubMed_Title>
      <Author>Ciszak, E., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1992)89:6644-6648</Journal>
      <PubMed_ID>1631168</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Wild type human transthyretin (TTR) complexed with GC-1 (TTRwt:GC-1)</PDB_Title>
      <PDB_ID>3NEE</PDB_ID>
      <Resolution>1.55</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3NEE</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The binding of synthetic triiodo l-thyronine analogs to human transthyretin: molecular basis of cooperative and non-cooperative ligand recognition.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2011)173:323-332</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20937391?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of transthyretin variant T60A at acidic pH</PDB_Title>
      <PDB_ID>3DO4</PDB_ID>
      <Resolution>2.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3DO4</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Amyloidogenic potential of transthyretin variants: Insights from structural and computational analyses</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-2,6-dibromo-4-(2,6-dimethoxystyryl)aniline</PDB_Title>
      <PDB_ID>3IMW</PDB_ID>
      <Resolution>1.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMW</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420162</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH DICLOFENAC</PDB_Title>
      <PDB_ID>1DVX</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVX</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420139</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF TRANSTHYRETIN IN COMPLEX WITH LIGAND C-3</PDB_Title>
      <PDB_ID>4ABV</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4ABV</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420180</ASD_Ligand>
      <PubMed_Title>Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites.</PubMed_Title>
      <Author>Tomar, D., et al.</Author>
      <Journal>Plos One(2012)7:43522</Journal>
      <PubMed_ID>22973437</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in complex with 3,5-Dibromo-4-hydroxystilbene</PDB_Title>
      <PDB_ID>3CN1</PDB_ID>
      <Resolution>1.52</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CN1</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420142</ASD_Ligand>
      <PubMed_Title>Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:6348-6358</Journal>
      <PubMed_ID>18811132</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The monoclinic crystal struture of transthyretin in complex with diethylstilbestrol</PDB_Title>
      <PDB_ID>1TZ8</PDB_ID>
      <Resolution>1.85</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TZ8</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The crystal structure of transthyretin in complex with diethylstilbestrol: a promising template for the design of amyloid inhibitors</PubMed_Title>
      <Author>Morais-de-Sa, E.M., et al.</Author>
      <Journal>J.Biol.Chem.(2004)279:53483-53490</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15469931?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with 4-(3-(2-flourophenoxy)propyl)-3,5-dimethyl-1H-pyrazole</PDB_Title>
      <PDB_ID>3P3T</PDB_ID>
      <Resolution>1.45</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P3T</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420175</ASD_Ligand>
      <PubMed_Title>Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.</PubMed_Title>
      <Author>Alhamadsheh, M.M., et al.</Author>
      <Journal>Sci Transl Med(2011)3:97ra81-97ra81</Journal>
      <PubMed_ID>21865539</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with (Z)-5-(3,5-dibromo-4-hydroxybenzylidene)-imino-1-methylimidazolidin-4-one</PDB_Title>
      <PDB_ID>3P3S</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3P3S</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420174</ASD_Ligand>
      <PubMed_Title>Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity.</PubMed_Title>
      <Author>Alhamadsheh, M.M., et al.</Author>
      <Journal>Sci Transl Med(2011)3:97ra81-97ra81</Journal>
      <PubMed_ID>21865539</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the F87M/L110M mutant of human transthyretin at pH 7.5</PDB_Title>
      <PDB_ID>3GRG</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GRG</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Novel Zn2+-binding sites in human transthyretin: implications for amyloidogenesis and retinol-binding protein recognition.</PubMed_Title>
      <Author>Palmieri, L.de.C., et al.</Author>
      <Journal>J.Biol.Chem.(2010)285:31731-31741</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20659897?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>a covalent dimer of transthyretin that affects the amyloid pathway</PDB_Title>
      <PDB_ID>1QWH</PDB_ID>
      <Resolution>1.36</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1QWH</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Kinetic stabilization of the native state by protein engineering: implications for inhibition of transthyretin amyloidogenesis.</PubMed_Title>
      <Author>Foss, T.R., et al.</Author>
      <Journal>J.Mol.Biol.(2005)347:841-854</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15769474?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with N-(3,5-Dibromo-4-hydroxyphenyl)-3,5-dimethyl-4-hydroxybenzamide</PDB_Title>
      <PDB_ID>3ESP</PDB_ID>
      <Resolution>1.31</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3ESP</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420149</ASD_Ligand>
      <PubMed_Title>Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2009)52:1115-1125</Journal>
      <PubMed_ID>19191553</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>The crystal structure of 2,4-dinitrophenol in complex with the amyloidogenic variant Transthyretin Leu 55 Pro</PDB_Title>
      <PDB_ID>2B14</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2B14</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420120</ASD_Ligand>
      <PubMed_Title>The binding of 2,4-dinitrophenol to wild-type and amyloidogenic transthyretin</PubMed_Title>
      <Author>Morais-de-Sa, E., et al.</Author>
      <Journal>ACTA CRYSTALLOGR.,SECT.D(2006)62:512-519</Journal>
      <PubMed_ID>16627944</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin in complex with lumiracoxib</PDB_Title>
      <PDB_ID>4IK6</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4IK6</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420201</ASD_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin in complex with lumiracoxib</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>THE X-RAY CRYSTAL STRUCTURE REFINEMENTS OF NORMAL HUMAN TRANSTHYRETIN AND THE AMYLOIDOGENIC VAL30MET VARIANT TO 1.7 ANGSTROMS RESOLUTION</PDB_Title>
      <PDB_ID>1TTC</PDB_ID>
      <Resolution>1.7</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1TTC</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The x-ray crystal structure refinements of normal human transthyretin and the amyloidogenic Val-30--&gt;Met variant to 1.7-A resolution.</PubMed_Title>
      <Author>Hamilton, J.A., et al.</Author>
      <Journal>J.Biol.Chem.(1993)268:2416-2424</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/8428915?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) in complex with 1,3-Dibromo-2-hydroxy-5-phenoxybenzene</PDB_Title>
      <PDB_ID>3CN3</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3CN3</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420144</ASD_Ligand>
      <PubMed_Title>Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies.</PubMed_Title>
      <Author>Johnson, S.M., et al.</Author>
      <Journal>J.Med.Chem.(2008)51:6348-6358</Journal>
      <PubMed_ID>18811132</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>HUMAN TRANSTHYRETIN (PREALBUMIN) COMPLEX WITH FLUFENAMIC ACID (2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO] BENZOIC ACID)</PDB_Title>
      <PDB_ID>1BM7</PDB_ID>
      <Resolution>2.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1BM7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710002</ASD_Ligand>
      <PubMed_Title>Inhibiting transthyretin conformational changes that lead to amyloid fibril formation.</PubMed_Title>
      <Author>Peterson, S.A., et al.</Author>
      <Journal>Proc.Natl.Acad.Sci.USA(1998)95:12956-12960</Journal>
      <PubMed_ID>9789022</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of the transthyretin mutant A108Y/L110E solved in space group C2</PDB_Title>
      <PDB_ID>1SOQ</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1SOQ</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The beta-strand D of transthyretin trapped in two discrete conformations</PubMed_Title>
      <Author>Hornberg, A., et al.</Author>
      <Journal>Biochim.Biophys.Acta(2004)1700:93-104</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15210129?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>V30M mutant human transthyretin (TTR) (apoV30M) pH 7.5</PDB_Title>
      <PDB_ID>3KGS</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3KGS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Conformational differences between the wild type and V30M mutant transthyretin modulate its binding to genistein: implications to tetramer stability and ligand-binding.</PubMed_Title>
      <Author>Trivella, D.B., et al.</Author>
      <Journal>J.Struct.Biol.(2010)170:522-531</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/20211733?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Human transthyretin (TTR) complexed with (E)-3-(2-methoxybenzylideneaminooxy)propanoic acid (inhibitor 13)</PDB_Title>
      <PDB_ID>3GS7</PDB_ID>
      <Resolution>1.8</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3GS7</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420155</ASD_Ligand>
      <PubMed_Title>Novel transthyretin amyloid fibril formation inhibitors: synthesis, biological evaluation, and X-ray structural analysis.</PubMed_Title>
      <Author>Palaninathan, S.K., et al.</Author>
      <Journal>Plos One(2009)4:e6290-e6290</Journal>
      <PubMed_ID>19621084</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>CRYSTAL STRUCTURE OF HUMAN TRANSTHYRETIN IN COMPLEX WITH FLURBIPROFEN</PDB_Title>
      <PDB_ID>1DVT</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1DVT</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420045</ASD_Ligand>
      <PubMed_Title>Rational design of potent human transthyretin amyloid disease inhibitors.</PubMed_Title>
      <Author>Klabunde, T., et al.</Author>
      <Journal>Nat.Struct.Biol.(2000)7:312-321</Journal>
      <PubMed_ID>10742177</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-N-(3-(4-hydroxy-3,5-dimethylstyryl)phenyl)acrylamide</PDB_Title>
      <PDB_ID>4HJU</PDB_ID>
      <Resolution>1.35</Resolution>
      <PDB_Method>X-ray</PDB_Method>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4HJU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420197</ASD_Ligand>
      <PubMed_Title>Stilbene vinyl sulfonamides as fluorogenic sensors of and traceless covalent kinetic stabilizers of transthyretin that prevent amyloidogenesis.</PubMed_Title>
      <Author>Suh, E.H., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:17869-17880</Journal>
      <PubMed_ID>24180271</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Transthyretin in complex with (E)-4-(3-aminostyryl)-2,6-dibromoaniline</PDB_Title>
      <PDB_ID>3IMU</PDB_ID>
      <Resolution>1.4</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3IMU</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420160</ASD_Ligand>
      <PubMed_Title>A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity.</PubMed_Title>
      <Author>Choi, S., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2010)132:1359-1370</Journal>
      <PubMed_ID>20043671</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Kinetic Stabilization of transthyretin through covalent modification of K15 by 4-bromo-3-(5-(3,5-dichloro-4-hydroxyphenyl)-1,3,4-oxadiazol-2-yl)-benzenesulfonamide</PDB_Title>
      <PDB_ID>4FI8</PDB_ID>
      <Resolution>1.22</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4FI8</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD10420192</ASD_Ligand>
      <PubMed_Title>Aromatic Sulfonyl Fluorides Covalently Kinetically Stabilize Transthyretin to Prevent Amyloidogenesis while Affording a Fluorescent Conjugate.</PubMed_Title>
      <Author>Grimster, N.P., et al.</Author>
      <Journal>J.Am.Chem.Soc.(2013)135:5656-5668</Journal>
      <PubMed_ID>23350654</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>AN ENGINEERED TRANSTHYRETIN MONOMER THAT IS NON-AMYLOIDOGENIC - UNLESS PARTIALLY DENATURED</PDB_Title>
      <PDB_ID>1GKO</PDB_ID>
      <Resolution>2.1</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1GKO</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>An Engineered Transthyretin Monomer that is Nonamyloidogenic, Unless It is Partially Denatured</PubMed_Title>
      <Author>Jiang, X., et al.</Author>
      <Journal>Biochemistry(2001)40:11442</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11560492?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Crystal structure of human transthyretin variant A25T in complex with flufenamic acid.</PDB_Title>
      <PDB_ID>3OZL</PDB_ID>
      <Resolution>1.9</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=3OZL</PDB_URL>
      <Has_Ligand>Yes</Has_Ligand>
      <ASD_Ligand>ASD06710002</ASD_Ligand>
      <PubMed_Title>Crystal structure of human transthyretin variant A25T in complex with flufenamic acid.</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Structure of TTR R104H: a non-amyloidogenic variant with protective clinical effects</PDB_Title>
      <PDB_ID>1X7T</PDB_ID>
      <Resolution>1.6</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1X7T</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>X-ray crystallographic studies of two transthyretin variants: further insights into amyloidogenesis.</PubMed_Title>
      <Author>Neto-Silva, R.M., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2005)61:333-339</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/15735344?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>MONOCLINIC FORM OF HUMAN TRANSTHYRETIN COMPLEXED WITH THYROXINE (T4)</PDB_Title>
      <PDB_ID>1ICT</PDB_ID>
      <Resolution>3.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=1ICT</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Structure of a new polymorphic monoclinic form of human transthyretin at 3 A resolution reveals a mixed complex between unliganded and T4-bound tetramers of TTR.</PubMed_Title>
      <Author>Wojtczak, A., et al.</Author>
      <Journal>Acta Crystallogr.,Sect.D(2001)57:957-967</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/11418763?dopt=Abstract</PubMed_ID>
    </PDB>
  </PDB_List>
  <Fold>
    <SCOP_Class>All beta proteins</SCOP_Class>
    <SCOP_URL>http://scop.mrc-lmb.cam.ac.uk/scop/data/scop.b.c.d.e.b.b.html</SCOP_URL>
    <CATH_Class>Class 2: Mainly Beta </CATH_Class>
    <CATH_URL>http://www.cathdb.info/pdb/1bm7</CATH_URL>
  </Fold>
  <AllostericSite_List>
    <AllostericSite>
      <Site_Detail>site,35,Lys;site,130,Leu</Site_Detail>
      <Site_Reference>Trivella DB, et al. J Struct Biol. 2010,170(3):522-531.;Jaffe EK. Curr Top Med Chem. 2013,13(1):55-63.</Site_Reference>
      <Site_Type>Morpheein model</Site_Type>
      <PDB_ID>3KGT;3KGU</PDB_ID>
      <PubMed_ID>20211733;23409765</PubMed_ID>
    </AllostericSite>
  </AllostericSite_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD01010031</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01140129</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01240003</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD01328023</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD02210006</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD03090008</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD04320001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05660009</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06710002</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD06898001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420001</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420002</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420003</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420004</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420005</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420006</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420007</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420008</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420009</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420010</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420011</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420012</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420013</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420014</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420015</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420016</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420017</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420018</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420019</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420020</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420021</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420022</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420023</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420024</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420025</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420026</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420027</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420028</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420029</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420031</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420032</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420034</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420035</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420036</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420038</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420039</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420040</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420041</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420042</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420043</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420044</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420046</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420047</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420048</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420049</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420050</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420051</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420052</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420053</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420056</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420057</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420058</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420059</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420060</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420062</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420063</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420064</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420065</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420066</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420067</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420068</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420069</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420070</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420071</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420072</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420073</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420075</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420076</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420077</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420080</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420081</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420082</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420083</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420084</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420085</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420086</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420087</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420088</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420090</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420091</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420092</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420093</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420094</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420095</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420096</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420097</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420098</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420099</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420100</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420102</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420103</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420104</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420105</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420106</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420107</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420108</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420109</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420110</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420111</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420112</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420113</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420114</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420115</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420116</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420117</ASD_ID>
      <Modulator_Feature>Regulator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420118</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420119</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420120</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420123</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420124</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420125</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420126</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420127</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420128</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420129</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420130</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420131</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420132</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420133</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420134</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420136</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420139</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420140</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420141</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420142</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420143</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420144</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420145</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420147</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420148</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420149</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420150</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420151</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420152</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420153</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420154</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420155</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420156</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420157</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420158</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420159</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420160</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420161</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420162</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420163</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420165</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420166</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420167</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420173</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420174</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420175</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420176</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420178</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420179</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420180</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420181</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420182</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420183</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420184</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420185</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420188</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420189</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420190</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420191</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420192</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420193</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420194</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420195</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420196</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420197</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420198</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420201</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420203</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420205</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420208</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420209</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420210</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD10420212</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD11030079</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2013-05-13</Create_Date>
</Organism_Record>